{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:38:50Z","timestamp":1784831930447,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014812","name":"Nordic Pharma Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.esmoop.2023.101199","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T08:29:35Z","timestamp":1680510575000},"page":"101199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"C.J.A.","family":"Punt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bodoky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Osterlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Teske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2023.101199_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14740338.2011.546342","article-title":"Capecitabine and hand-foot syndrome","volume":"10","author":"Saif","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.esmoop.2023.101199_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2017.02.009","article-title":"Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch colorectal cancer group","volume":"76","author":"Kwakman","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101199_bib3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2023.101199_bib4","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/14656566.2016.1186649","article-title":"Oral drugs in the treatment of metastatic colorectal cancer","volume":"17","author":"Kwakman","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.esmoop.2023.101199_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/13543780902729412","article-title":"S-1: a promising new oral fluoropyrimidine derivative","volume":"18","author":"Saif","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.esmoop.2023.101199_bib6","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/annonc\/mdx122","article-title":"Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group","volume":"28","author":"Kwakman","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100427","article-title":"Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study","volume":"7","author":"Osterlund","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2023.101199_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2022.02.004","article-title":"Systematic review and non-inferiority meta-analysis of randomised phase II\/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer","volume":"166","author":"Derksen","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101199_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib11","first-page":"1161","article-title":"Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine","volume":"18","author":"Scheithauer","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.esmoop.2023.101199_bib12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.1989.7.4.425","article-title":"A\u00a0prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study","volume":"7","author":"Lokich","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib14","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/annonc\/mdi116","article-title":"A\u00a0randomised comparison between 6 months of bolus fluorouracil\/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer","volume":"16","author":"Chau","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib15","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1200\/JCO.2008.16.7759","article-title":"Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil\/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials","volume":"26","author":"Arkenau","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(22)00334-X","article-title":"Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study","volume":"8","author":"Andr\u00e9","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2023.101199_bib17","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib18","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ijc.25369","article-title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer","volume":"128","author":"Ducreux","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2023.101199_bib19","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2006.09.8467","volume":"25","author":"Diaz-Rubio","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib20","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2006.09.2684","article-title":"Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group","volume":"25","author":"Porschen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1634\/theoncologist.2014-0219","article-title":"The hand-foot skin reaction and quality of life questionnaire: an assessment tool for oncology","volume":"20","author":"Anderson","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2023.101199_bib22","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","article-title":"HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome","volume":"16","author":"Sibaud","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2023.101199_bib23","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2023.101199_bib24","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","article-title":"Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial","volume":"16","author":"Hegewisch-Becker","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol Rev"},{"key":"10.1016\/j.esmoop.2023.101199_bib27","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.2003.09.016","article-title":"Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"21","author":"Scheithauer","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib28","first-page":"e388","article-title":"A\u00a0systematic review and meta-analysis on the association between hand-foot syndrome (HFS) and cancer chemotherapy efficacy","volume":"170","author":"Falcone","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.esmoop.2023.101199_bib29","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/bjc.2012.434","article-title":"Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer","volume":"107","author":"Hofheinz","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2023.101199_bib30","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/0284186X.2016.1278459","article-title":"Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients","volume":"56","author":"Kwakman","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib31","first-page":"229","article-title":"Long-term safety data on S-1 administered after previous intolerance to capecitabine-containing systemic treatment for metastatic colorectal cancer","volume":"21","author":"Punt","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2023.101199_bib32","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy","volume":"53","author":"Yeh","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.esmoop.2023.101199_bib33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/0284186X.2019.1711164","article-title":"Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer","volume":"59","author":"Dyhl-Polk","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib35","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1002\/onco.13536","article-title":"Myocardial ischemia induced by 5-fluorouracil: a prospective electrocardiographic and cardiac biomarker study","volume":"26","author":"Dyhl-Polk","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2023.101199_bib36","article-title":"Treatment-related coronary disorders of fluoropyrimidine administration: a systematic review and meta-analysis","volume":"13","author":"Lu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.esmoop.2023.101199_bib37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaccao.2021.11.001","article-title":"Risk for myocardial infarction following 5-fluorouracil treatment in patients with gastrointestinal cancer: a nationwide registry-based study","volume":"3","author":"Shanmuganathan","year":"2021","journal-title":"JACC Cardio Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaccao.2020.12.005","article-title":"The incidence, risk factors, and outcomes with 5-fluorouracil-associated coronary vasospasm","volume":"3","author":"Zafar","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103346","article-title":"Risk factors of fluoropyrimidine induced cardiotoxicity among cancer patients: a systematic review and meta-analysis","volume":"162","author":"Li","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2023.101199_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A\u00a0systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.esmoop.2023.101199_bib41","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","article-title":"Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle","volume":"28","author":"Jensen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib42","first-page":"4426","article-title":"Cardiotoxicity of fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management","volume":"10","author":"Jurczyk","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.esmoop.2023.101199_bib43","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.esmoop.2023.101199_bib44","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.esmoop.2023.101199_bib45","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jamaoncol.2021.1144","article-title":"Identification of risk of cardiovascular disease by automatic quantification of coronary artery calcifications on radiotherapy planning CT scans in patients with breast cancer","volume":"7","author":"Gal","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2023.101199_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265767","article-title":"The efficacy and safety of cardio-protective therapy in patients with 5-FU (fluorouracil)-associated coronary vasospasm","volume":"17","author":"Zafar","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2023.101199_bib47","first-page":"52","article-title":"Bolus 5-fluorouracil (5-FU) in combination with oxaliplatin is safe and well tolerated in patients who experienced coronary vasospasm with infusional 5-FU or capecitabine","volume":"18","author":"Chakrabarti","year":"2019","journal-title":"Clin Colorect Cancer"},{"key":"10.1016\/j.esmoop.2023.101199_bib48","first-page":"8","article-title":"Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity","volume":"12","author":"Deboever","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2023.101199_bib49","first-page":"64","article-title":"Efficacy and cardiotoxic safety profile of raltitrexed in fluoropyrimidines-pretreated or high-risk cardiac patients with GI malignancies: large single-center experience","volume":"18","author":"Khan","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2023.101199_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102218","article-title":"Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone","volume":"98","author":"Glimelius","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2023.101199_bib51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000443984","article-title":"New perspectives in the treatment of advanced gastric cancer: S-1 as a novel oral 5-FU therapy in combination with cisplatin","volume":"62","author":"Mahlberg","year":"2017","journal-title":"Chemotherapy"},{"key":"10.1016\/j.esmoop.2023.101199_bib52","first-page":"13","article-title":"5-FU induced cardiotoxicity: case series and review of the literature","volume":"5","author":"Yuan","year":"2019","journal-title":"Cardiooncology"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923004210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923004210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:31:53Z","timestamp":1761856313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923004210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2059702923004210"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101199","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101199"}}